|
1
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group: Metastatic
non-small cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii27–39. 2014. View Article : Google Scholar
|
|
2
|
Field JK, Oudkerk M, Pedersen JH and Duffy
SW: Prospects for population screening and diagnosis of lung
cancer. Lancet. 382:732–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curioni-Fontecedro A, Husmann L, Soldini D
and Stahel RA: Primary non-small cell lung cancer response upon
treatment with denosumab. Lung Cancer. 82:506–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barr FA, Silljé HH and Nigg EA: Polo-like
kinases and the orchestration of cell division. Nat Rev Mol Cell
Biol. 5:429–440. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cholewa BD, Liu X and Ahmad N: The role of
polo-like kinase 1 in carcinogenesis: Cause or consequence? Cancer
Res. 73:6848–6855. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takai N, Hamanaka R, Yoshimatsu J and
Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene.
24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weichert W, Schmidt M, Gekeler V, Denkert
C, Stephan C, Jung K, Loening S, Dietel M and Kristiansen G:
Polo-like kinase 1 is overexpressed in prostate cancer and linked
to higher tumor grades. Prostate. 60:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM,
Zhang Y, Du XL, Luo ML, Xu X, Han YL, et al: Overexpression of PLK1
is associated with poor survival by inhibiting apoptosis via
enhancement of survivin level in esophageal squamous cell
carcinoma. Int J Cancer. 124:578–588. 2009. View Article : Google Scholar
|
|
9
|
Weichert W, Kristiansen G, Schmidt M,
Gekeler V, Noske A, Niesporek S, Dietel M and Denkert C: Polo-like
kinase 1 expression is a prognostic factor in human colon cancer.
World J Gastroenterol. 11:5644–5650. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang ZX, Xue D, Liu ZL, Lu BB, Bian HB,
Pan X and Yin YM: Overexpression of polo-like kinase 1 and its
clinical significance in human non-small cell lung cancer. Int J
Biochem Cell Biol. 44:200–210. 2012. View Article : Google Scholar
|
|
11
|
Spänkuch-Schmitt B, Wolf G, Solbach C,
Loibl S, Knecht R, Stegmüller M, von Minckwitz G, Kaufmann M and
Strebhardt K: Downregulation of human polo-like kinase activity by
antisense oligonucleotides induces growth inhibition in cancer
cells. Oncogene. 21:3162–3171. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W, Dahlberg JE and Tam W: MicroRNAs
in tumorigenesis: A primer. Am J Pathol. 171:728–738. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Papagiannakopoulos T and Kosik KS:
MicroRNAs: Regulators of oncogenesis and stemness. BMC Med.
6:152008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bowen T, Jenkins RH and Fraser DJ:
MicroRNAs, transforming growth factor beta-1, and tissue fibrosis.
J Pathol. 229:274–285. 2013. View Article : Google Scholar
|
|
17
|
Ito T, Sato F, Kan T, Cheng Y, David S,
Agarwal R, Paun BC, Jin Z, Olaru AV, Hamilton JP, et al: Polo-like
kinase 1 regulates cell proliferation and is targeted by miR-593*
in esophageal cancer. International journal of cancer. Int J
Cancer. 129:2134–2146. 2011. View Article : Google Scholar :
|
|
18
|
Liu J, Lu KH, Liu ZL, Sun M, De W and Wang
ZX: MicroRNA-100 is a potential molecular marker of non-small cell
lung cancer and functions as a tumor suppressor by targeting
polo-like kinase 1. BMC Cancer. 12:5192012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Savi F, Forno I, Faversani A, Luciani A,
Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, et al:
miR-296/Scribble axis is deregulated in human breast cancer and
miR-296 restoration reduces tumour growth in vivo. Clin Sci (Lond).
127:233–242. 2014. View Article : Google Scholar
|
|
20
|
Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH,
Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, et al: MicroRNA-296-5p
(miR-296-5p) functions as a tumor suppressor in prostate cancer by
directly targeting Pin1. Biochim Biophys Acta. 1843:2055–2066.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vaira V, Faversani A, Martin NM, Garlick
DS, Ferrero S, Nosotti M, Kissil JL, Bosari S and Altieri DC:
Regulation of lung cancer metastasis by Klf4-Numb-like signaling.
Cancer Res. 73:2695–2705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu J, Li A, Hong SM, Hruban RH and Goggins
M: MicroRNA alterations of pancreatic intraepithelial neoplasias.
Clin Cancer Res. 18:981–992. 2012. View Article : Google Scholar :
|
|
23
|
Corbetta S, Vaira V, Guarnieri V,
Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini
I, Bisceglia M, Beck-Peccoz P, et al: Differential expression of
microRNAs in human parathyroid carcinomas compared with normal
parathyroid tissue. Endocr Relat Cancer. 17:135–146. 2010.
View Article : Google Scholar
|
|
24
|
Weitzer S and Uhlmann F: Chromosome
segregation: Playing polo in prophase. Dev Cell. 2:381–382. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie S, Xie B, Lee MY and Dai W: Regulation
of cell cycle checkpoints by polo-like kinases. Oncogene.
24:277–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McInnes C and Wyatt MD: PLK1 as an
oncology target: Current status and future potential. Drug Discov
Today. 16:619–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McCarroll JA, Dwarte T, Baigude H, Dang J,
Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, et
al: Therapeutic targeting of polo-like kinase 1 using
RNA-interfering nanoparticles (iNOPs) for the treatment of
non-small cell lung cancer. Oncotarget. 6:12020–12034. 2014.
View Article : Google Scholar
|
|
28
|
Bhola NE, Jansen VM, Bafna S, Giltnane JM,
Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, et al:
Kinome-wide functional screen identifies role of PLK1 in
hormone-independent, ER-positive breast cancer. Cancer Res.
75:405–414. 2015. View Article : Google Scholar
|
|
29
|
Degenhardt Y and Lampkin T: Targeting
Polo-like kinase in cancer therapy. Clin Cancer Res. 16:384–389.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cholewa BD, Pellitteri-Hahn MC, Scarlett
CO and Ahmad N: Large-scale label-free comparative proteomics
analysis of polo-like kinase 1 inhibition via the small-molecule
inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma
cells. J Proteome Res. 13:5041–5050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Davis-Dusenbery BN and Hata A: MicroRNA in
cancer: The involvement of aberrant microRNA biogenesis regulatory
pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar
|
|
32
|
Mavrakis KJ, Leslie CS and Wendel HG:
Cooperative control of tumor suppressor genes by a network of
oncogenic microRNAs. Cell Cycle. 10:2845–2849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoon AR, Gao R, Kaul Z, Choi IK, Ryu J,
Noble JR, Kato Y, Saito S, Hirano T, Ishii T, et al: MicroRNA-296
is enriched in cancer cells and downregulates p21WAF1 mRNA
expression via interaction with its 3′ untranslated region. Nucleic
Acids Res. 39:8078–8091. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vasilatou D, Papageorgiou S, Pappa V,
Papageorgiou E and Dervenoulas J: The role of microRNAs in normal
and malignant hematopoiesis. Eur J Haematol. 84:1–16. 2010.
View Article : Google Scholar
|
|
35
|
Godlewski J, Nowicki MO, Bronisz A,
Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca
EA and Lawler S: Targeting of the Bmi-1 oncogene/stem cell renewal
factor by microRNA-128 inhibits glioma proliferation and
self-renewal. Cancer Res. 68:9125–9130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu D, Green B, Marrone A, Guo Y, Kadlubar
S, Lin D, Fuscoe J, Pogribny I and Ning B: Suppression of CYP2C9 by
microRNA hsa-miR-128-3p in human liver cells and association with
hepatocellular carcinoma. Sci Rep. 5:85342015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okumura T, Shimada Y, Moriyama M, Takei Y,
Omura T, Sekine S, Nagata T, Shimizu K and Tsukada K: MicroRNA-203
inhibits the progression of esophageal squamous cell carcinoma with
restored epithelial tissue architecture in vivo. Int J Oncol.
44:1923–1932. 2014.PubMed/NCBI
|
|
38
|
Wei Y, Du Y, Chen X, Li P, Wang Y, Zang W,
Zhao L, Li Z and Zhao G: Expression patterns of microRNA-218 and
its potential functions by targeting CIP2A and BMI1 genes in
melanoma. Tumour Biol. 35:8007–8015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B,
Zhou L, Song WJ and Dou KF: MicroRNA-135a inhibits cell
proliferation by targeting Bmi1 in pancreatic ductal
adenocarcinoma. Int J Biol Sci. 10:733–745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vaira V, Faversani A, Dohi T, Montorsi M,
Augello C, Gatti S, Coggi G, Altieri DC and Bosari S: miR-296
regulation of a cell polarity-cell plasticity module controls tumor
progression. Oncogene. 31:27–38. 2012. View Article : Google Scholar :
|
